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ABSTRACT
The interventional cardiology is growing and evolving. Many complex procedures are now 
performed outside the operating room to manage cardiovascular pathologies which had been 
traditionally treated with cardiac surgery. Appropriate sedation strategy is crucial for improved 
patient comfort and successful procedure while ensuring safety. Sedation for cardiovascular 
intervention is frequently challenging, especially in critically-ill, high-risk patients. This 
review addresses pre-procedure evaluation and preparation of patients, proper monitoring, 
commonly used sedatives and analgesics, and considerations for specific procedures. 
Appropriate depth of sedation and analgesia should be balanced with patient, procedural and 
institutional factors. Understanding of the pharmacology of sedatives/analgesics, vigilant 
monitoring, ability and proper preparation for management of potential complications may 
improve outcomes in patients undergoing sedation for cardiovascular procedures.
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INTRODUCTION
The interventional cardiology is rapidly growing both in number and complexity. As an 
integral component of cardiologic procedures, the demand for sedation is also increasing. 
The goal of procedural sedation is minimizing patients' discomfort and ensuring safety. 
Depending on the depth, sedation provides anxiolysis, progressive impairment of 
consciousness, amnesia and analgesia. Appropriate sedation enables patients' immobility 
during the procedure, facilitating successful procedure while reducing the risk of 
complication by optimizing environment, as well as improved overall patient satisfaction. 
Achieving this goal is sometimes challenging, especially in case of critically ill, high-
risk patients undergoing complex procedures. Adequate pre-procedural evaluation and 
preparation, understanding pharmacology of sedatives and analgesics, proper monitoring, 
ability to rescue patients from unintended deep sedation or related adverse events are 
mandatory to provide safe and satisfactory sedation in cardiovascular intervention.
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Cardiovascular Interventions
THE DEPTH OF SEDATION
The depth of sedation is a continuum from minimal, moderate, deep sedation to general 
anesthesia (Table 1).1) Minimal sedation refers a drug-induced anxiolysis during which 
patients respond normally to verbal stimulation. Moderate sedation, also called as 
‘conscious’ sedation, indicates an impairment of consciousness during which patients are 
able to respond purposefully to verbal or light tactile stimulation. During deep sedation, 
patients respond only after repeated or painful stimulation, and assistance to maintain patent 
airway may be needed. Patients under general anesthesia cannot be aroused even by painful 
stimulation, airway patency is usually not maintained without assistance, and spontaneous 
ventilation is often impaired, requiring positive pressure ventilation. In general, moderate 
(conscious) sedation is ideal for most percutaneous cardiovascular intervention, however, 
deep sedation may be required for some patients and/or procedures. More importantly, 
because sedation is a continuum within a wide range of levels of consciousness, transition to 
a deeper level may be rapid and not always predictable. Thus, the sedation provider should 
recognize drifting level of sedation through continuous monitoring, and also be able to 
rescue the patient from the deeper level of sedation and related complications.2)
PRE-PROCEDURE PATIENT ASSESSMENT AND 
PREPARATION
The sedation provider should be aware of any medical conditions or comorbidities that 
potentially increase the likelihood of complications, by review of previous medical records 
and interview with the patients or caregivers. These include abnormalities of major organ 
system, any allergies, obstructive sleep apnea, morbid obesity, history of psychotropic drug 
use, and previous experience with sedation.3) The physical examination before sedation 
should be focused on the respiratory and cardiovascular system. The evaluation of airway is 
particularly important. Compromises in neck mobility and mouth opening, facial anomaly, 
teeth condition, neck mass, breathing sound should be checked before the administration 
of sedation.
Pre-sedation fasting requirements are similar with those for general anesthesia.4) Patients 
are allowed to drink clear liquid (water, sugar water, juice without pulp) until 2 hours 
before sedation. Minimum fasting time for light meal and non-human milk is 6 hours, 
and fasting 8 h or more is recommended for fatty food or meat. Routine administration 
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Table 1. The continuum of sedation
Description Minimal sedation Moderate sedation Deep sedation General anesthesia
Responsiveness Normal Purposeful response 
to verbal or tactile 
stimulation
Purposeful response 






Not required Not required Occasionally 
required
Frequently required















remember very little 
thing
Asleep, mostly 
do not remember 
anything
of gastrointestinal stimulants, medications that block gastric acid secretion, antacids or 
antiemetics are not recommended. These guidelines are mainly based on studies which 
investigated gastric volume and pH,5) and the impact of pre-sedation fasting time on 
patients' outcome is not obvious.6)7) However, considering that pulmonary aspiration is a 
rare but frequently fatal complication, and moderate sedation can be converted to deep 
sedation or general anesthesia during procedure, it is generally recommended to conform 
the fasting guideline.
PATIENT MONITORING
Most of sedation-related complications are caused by drug-overdose. According to an 
analysis of the American Society of Anesthesiologists (ASA) Closed Claims database, 
respiratory depression was responsible for 21% of sedation-related claims, and almost half 
of these claims were judged as ‘preventable’ if proper monitoring were applied with vigilance 
and alarm system.8) It is recommended that all patients undergoing procedural sedation is 
monitored for respiratory function, hemodynamics and the depth of sedation.9) In addition 
to monitoring devices, it should be emphasized that a designated, trained personal for 
monitoring of the patient is required to attend throughout the procedure.1)
Respiratory and hemodynamic monitoring
Respiratory depression due to an overdose of sedatives is the most common adverse event 
during sedation.10) All patients undergoing procedural sedation should be monitored 
for hypoxemia or desaturation by pulse oximetry.11) Because pulse oximetry measures 
arterial oxygen saturation, the detection of compromised respiratory activity can be 
delayed, especially if patients are receiving supplemental oxygen. For early detection 
of hypoventilation, monitoring exhaled carbon dioxide tension is superior than pulse 
oximetry.12) Early detection enables rapid interventions to relieve respiratory depression, 
including adjustment of drug dosing and the depth of sedation, patient stimulation, 
maneuvers for airway patency, assisted ventilation and supplemental oxygen. Indeed, 
capnography monitoring was demonstrated to reduce respiratory complication and improve 
patient safety during procedural sedation with benzodiazepines and opioids.13) The sedation 
provider should also observe vigilantly for qualitative clinical signs, such as movement of 
chest wall, suprasternal, intercostal, and subcostal retraction, gasping for air, and stridor.
For sedation during cardiovascular procedures, non-invasive blood pressure, heart rate and 
electrocardiography monitoring is recommended. Invasive blood pressure monitoring is 
occasionally required for the patients with advanced cardiovascular dysfunction.
Monitoring the depth of sedation
The depth of sedation should be monitored throughout the procedure. Patient may 
be uncomfortable with light sedation, whereas deep sedation has greater impact on 
cardiopulmonary function. Thus, the margin of safety for deeper level of sedation may 
be narrow, especially in patients with impaired cardiopulmonary function. The dose of 
sedatives and analgesics are carefully titrated according to the depth of sedation as most of 
sedation-related complications are associated with unintended deeper level of sedation. The 
sedation provider can monitor the depth of sedation by periodical verbal stimulation as well 
as other clinical signs. However, some clinicians advocate processed, digitalized form of 
electroencephalogram-derived monitor to monitor the level of consciousness.
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The bispectral index (BIS; Aspect Medical Systems, Norwood, MA, USA) is the one of the 
most popular monitors of processed electroencephalogram. It receives electroencephalogram 
signal via a single patch sensor attached on the forehead, analyzes and processes the signal 
into a single number, ranging 0 (isoelectric electroencephalographic activity) to 100. A BIS 
value between 90 and 100 indicates fully awaken status, a value between 70 and 90 represents 
light to moderate sedation. A BIS value of 60 to 70 indicates superficial anesthesia, and 
a value between 40 and 60 is regarded as an appropriate value for general anesthesia. 
Monitoring with BIS is continuous and more convenient than assessment of clinical signs 
alone, however, for relatively short procedures, addition of BIS monitoring seems to provide 
little benefit over conventional assessment of clinical signs. In a study comparing the BIS 
monitoring with clinical assessment, awareness, propofol requirement, desaturation and 
need for hemodynamic and respiratory support were all similar between the study groups 
in patients undergoing bronchoscopy.14) Moreover, the correlation between the BIS and the 
assessed sedation level was very weak.15) In contrast, procedures which take long time or 
require moderate to deep sedation may benefit from the BIS monitoring.16-18)
COMMONLY USED SEDATIVES AND ANALGESICS
Midazolam
Midazolam is a benzodiazepine with a rapid onset (1 to 5 minutes) and short duration of 
action (Table 2). It is the most commonly used agent for short procedures requiring light to 
moderate sedation. It confers anxiolysis and antegrade amnesia. Because it has no analgesic 
property, it is usually used in combination with opioids. It blunts central respiratory drive 
response to hypercapnia or hypoxia.19) The respiratory depressant effect is dose-dependent 
and might be increased with rapid intravenous bolus administration. A reduced dose is 
recommended for old age and patients with impaired cardiopulmonary function. Midazolam 
is thought to have minimal effect in terms of hemodynamic deterioration.20) Midazolam 
has negligible direct myocardial depressive effect and modest decrease in blood pressure 
can occur due to mild vasodilation and sympatholytic effect. However, both respiratory 
and cardiovascular effects are synergistic when midazolam is used in combination of other 
sedatives and analgesics, for example opioids, leading to severe respiratory depression and 
hypotension greater than expected by the effect of each drug.21) Midazolam is metabolized in 
liver, and the main metabolite, which possesses sedative activity, is rapidly cleared via kidney. 
Thus, in patients with liver cirrhosis or renal impairment, midazolam administration can 
result in profound sedation for longer duration.22)23)
Midazolam may induce agitation, restlessness, aggressiveness or hallucinations.24) This paradoxical 
disinhibitory reactions develop within several minutes after intravenous administration following 
transient sedation. It is reported to occur in <1% of midazolam administrations and thought to 
be associated with loss of cortical resistance and reduced serotonin control.25) Patient with alcohol 
abuse or psychologic disturbances are at increased risk of paradoxical reactions. The paradoxical 
reactions may be attenuated with flumazenil or haloperidol.26)27)
Propofol
Propofol is a sedative-hypnotic agent with no analgesic effect. It has rapid onset (<1 minute) 
and relatively short context-sensitive half-time, which enables smooth and quick recovery 
even after prolonged continuous infusion (Table 2). Propofol has little paradoxical excitatory 
effect and low incidence of nausea and vomiting.28) These favorable pharmacokinetic and 
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pharmacodynamics profile made it one of the most popular intravenous agents in modern 
anesthetic practice.
The pharmacokinetic model of propofol is described as a 3-compartmental model which 
consists of central, peripheral (lean tissues) and deep (fat tissues) compartment.29) 
Following intravenous bolus administration, propofol is rapidly redistributed to a peripheral 
compartment, resulting in fast offset of its clinical effect (5–10 minutes). Because propofol is 
lipophilic, the fat compartment acts as a reservoir after prolonged infusion. Redistribution 
from the fat compartment may delay the offset of action especially in obese patient.30) Time 
required for decrease in plasma concentrations are also significantly longer in the elderly.29) 
Nonetheless, recovery after prolonged infusion is relatively quicker compared with other 
hypnotics such as midazolam, because the rate of metabolism and excretion is faster than 
the rate of redistribution. The context-sensitive half-time of propofol is 25 minutes after 3 
hour-long infusion, whereas midazolam has a context-sensitive half-time of 70 minutes for 
a similar duration of infusion.31) Propofol is mainly metabolized in liver, and the metabolites, 
which have no hypnotic effect, are excreted via kidney.30)
Propofol is a potent respiratory depressant. An intravascular bolus administration may 
result in apnea. The dose, speed of injection and co-administered drugs, especially opioids, 
are associated with the incidence and duration of apnea.32) Propofol infusion at 100 µg/
kg/min induces a 40% decrease in tidal volume and a 20% increase in respiratory rate.33) 
Propofol also induces cardiovascular depression, with a greater extent compared with 
other intravascular sedative agents.34) Even in healthy individual with no cardiovascular 
impairment, propofol produces 25% to 40% decrease in systemic blood pressure. In 
addition to vasodilatory effect, it also decreases cardiac output and stroke volume. These 
cardiovascular effects are associated with sympatholytic activity and whether propofol has 
direct myocardial depressive effect is still controversial.35) Notably, peak hemodynamic effect 
of propofol tends to follow behind the hypnotic effect.36) So profound hypotension may 
manifest a few minutes after the patients fall into deeper level of sedation.
The most frequent complaints in patients who receive propofol is pain at injection site, which 
can be managed with concomitant use of lidocaine at the start of injection.37)38) Propofol has 
no physical dependence, however, it may result in euphoria with sense of ‘general well-
being’, predisposing a risk of addiction or abuse.39) Lipid-based formulation of propofol is 
susceptible to bacterial contamination and can induce life-threatening sepsis unless stored 
and handled appropriately in a sterile and aseptic manner.40)
Dexmedetomidine
Dexmedetomidine is an α-2 adrenergic receptor agonist which has anxiolytic, sedative and 
analgesic property (Table 2).41) Compared with clonidine, it is more selective and efficacious. 
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Table 2. Commonly used sedatives
Sedatives Dose Onset Hypnosis Analgesia Side effects
Midazolam 0.01–0.1 mg/kg 1–5 min ++ − Respiratory depression, paradoxical excitation
Propofol Bolus: 1–1.5 mg/kg <1 min ++ − Respiratory depression, hypotension, 
bradycardiaInfusion: 25–100 µg/kg/min
Dexmedetomidine 1 µg/kg over 10 min followed 
by infusion at 0.2–0.7 µg/kg/h
10–15 min + + Biphasic hemodynamic effect: hypotension, 
hypertension, bradycardia
Remifentanil 0.05–2 µg/kg/min <1 min − ++ Respiratory depression, chest wall rigidity, 
bradycardia, hypotension
It exerts sedative effect by binding to α-2 receptors in the locus coeruleus and analgesic effect 
by an action on α-2 receptors in spinal cord as well as locus coeruleus.42) Unlike other sedative 
drugs such as propofol and benzodiazepines, dexmedetomidine induces sedation through 
the endogenous sleep-promoting pathway.43) Thus, it produces a natural sleep-like patterns of 
the electroencephalogram, and patients receiving dexmedetomidine usually fall asleep when 
undisturbed, while they are easily arousable and cooperative. Dexmedetomidine has minimal 
respiratory depressive effect. Sedation with dexmedetomidine induces modest reduction in 
minute ventilation,44) however, ventilatory response to hypercapnia is unaffected even in deep 
sedation.45) Dexmedetomidine reduces the release of norepinephrine and sympathetic tone in 
the central nervous system, thus it can induce severe bradycardia.46)47) Transient hypertension 
can occur due to stimulation of peripheral α-2 receptors. Slow initial loading over 20 minutes 
may reduce the transient hypertension.48) In case of hypertension during initial loading, it 
is recommended to decrease subsequent continuous infusion rate. Hypotension can also 
occur, especially in old age, history of diabetes or hypertension, or with a large loading dose. 
Dexmedetomidine can be used alone or in combination with other sedatives/analgesics. 
Because dexmedetomidine exerts minimal respiratory depression, combined administration 
with other sedatives/analgesics provide excellent results without increased risk of respiratory 
complication.49)
Opioids
Owing to their strong analgesic efficacy, addition of opioids can ameliorate procedure-
related discomfort. Opioids have no hypnotic effect, however, it can reduce the 
requirements of other hypnotics when used in combination. Because the risk of 
respiratory and cardiovascular depression increases synergistically with other sedatives, 
special attention is needed in patients receiving opioids in combination with propofol 
or midazolam. Remifentanil is an ultra-short acting synthetic opioid, which has gained 
popularity recently for conscious sedation during painful procedures.50) It has rapid onset 
and short context-sensitive half time regardless of the duration of infusion. Recovery is 
rapid even after prolonged infusion and not affected by hepatic or renal function.51) Initial 
loading dose is not necessary, and an infusion at 0.05–2 µg/kg/min provides sufficient 
analgesia for most procedures (Table 2). However, respiratory depression is not infrequent 
even at subtherapeutic doses. Like other opioids, remifentanil infusion occasionally induces 
chest wall rigidity which impairs ventilation.
CONSIDERATIONS FOR SPECIFIC PROCEDURES
Catheter ablation for arrhythmias
Depending on the complexity of procedures, moderate sedation is feasible for most of cases, 
either with benzodiazepine, propofol, opioids or dexmedetomidine.52-54) However, in case of 
complex procedures, deep sedation or general anesthesia is occasionally required because the 
procedures can be lengthy and patient immobility is crucial for the induction and accurate 
mapping of the arrhythmogenic foci. In a trial comparing sedation versus general anesthesia 
for ablation of atrial fibrillation, general anesthesia was associated with shorter procedure 
time and higher arrhythmia-free rate.55) However, general anesthesia may predispose high 
incidence of esophageal injury, likely due to reduced esophageal motility and swallowing 
during general anesthesia.56) In addition, absence of feedback from patients might delay the 
detection of complications during the procedure.
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There has been a concern that sedatives/anesthetics have a potential to suppress arrhythmia 
inducibility, interfering successful ablation of supraventricular tachyarrhythmia. Most 
of sedatives/anesthetics including volatile anesthetics, propofol, remifentanil and 
dexmedetomidine may slow cardiac conduction, exert sympatholytic effect and reduce the 
ability to elicit arrhythmia, especially in deep sedation with high doses.57-59) A combination 
of benzodiazepine and fentanyl is thought to have less impact on arrhythmia inducibility.60) 
However, a concrete evidence for superiority of any particular agent in regard to the ability to 
elicit arrhythmia and impact on success rate of the procedure is lacking so far, thus sedative 
strategy should be chosen upon a balance of patient comfort, preference and experience of 
sedation provider, and arrhythmia inducibility.
Electrical cardioversion
Electrical cardioversion is highly stimulating and requires deep sedation to alleviate 
patient discomfort. However, because the period of stimulation is brief, short-acting 
agents are recommended for rapid recovery. Either benzodiazepines, opioids, and 
propofol can be used.61)62) Propofol may have advantage in terms of quick onset and offset 
of sedation, ease of titration, less nausea and vomiting, whereas it is associated with 
more frequent episode of apnea and hypotension.63) Despite the theoretical advantage of 
propofol, benzodiazepines are widely used due to its practitioner familiarity and minimal 
hemodynamic effects.
Pacemakers and implantable cardiac defibrillators
The insertion of pacemakers and implantable cardiac defibrillators can be performed under 
minimal to moderate sedation. Tunneling of leads to a subcutaneous pocket needs adequate 
local anesthesia. Like electrical cardioversion, defibrillation threshold test requires deep 
sedation. Some patients with advanced heart failure may not be able to tolerate the supine 
position due to orthopnea and these patients are extremely sensitive to sedatives and opioids. 
Deep sedation in patients with advanced hear failure frequently results in hemodynamic 
deterioration due to reduced sympathetic tone. Moreover, retention of carbon dioxide may 
worsen pulmonary hypertension and lead to right ventricular failure.
Percutaneous transluminal angioplasty
The prevalence of peripheral artery disease and need for an appropriated sedation analgesia 
for percutaneous transluminal angioplasty is increasing.64) Patients undergoing percutaneous 
transluminal angioplasty are usually old and at increased risk of cardiovascular event. 
Peripheral artery disease provokes broad spectrums of pain, and ballooning may elicit 
significant ischemic pain. Thus, adequate pain control is crucial. Opioids alone may provide 
sufficient analgesia. Combination of opioids such as remifentanil with benzodiazepines 
or propofol may improve sedation experience, however, it can increase a risk of respiratory 
depression.65) Addition of dexmedetomidine can confer both sedation and analgesia while 
sparing the dose of opioids and preserving the respiratory function.66)
CONCLUSION
Sedation for cardiovascular interventions is frequently challenging. To facilitate successful 
procedure and improve patients' experience and safety, appropriate depth of sedation and 
analgesia should be balanced with patient, procedural and institutional factors. Understanding 
the pharmacology of sedatives/analgesics, ability and proper setting for managing potential 
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complications, and clear communication between sedation provider and interventionist may 
improve outcomes in patients undergoing sedation for cardiovascular procedures.
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